Parainfluenza Virus Infection Among Human Immunodeficiency Virus (HIV)-Infected and HIV-Uninfected Children and Adults Hospitalized for Severe Acute Respiratory Illness in South Africa, 2009–2014

Adam L. Cohen,1,2,3 Philip K. Sahr,4,5 Florette Treurnicht,6 Sibongile Walaza,6,7 Michelle J. Groome,8,9 Kathleen Kahn,10,13,14 Halima Dawood,15,16 Ebrahim Variava,11,17 Stefano Tempia,1,2,6 Marthi Pretorius,18,19 Jocelyn Moyes,6
Steven A. S. Olorunju,20 Babatyi Malope-Kgokong,2 Lazarus Kuonza,4 Nicole Wolter,6,12 Anne von Gottberg,6,12 Shabir A. Madhi,6,8,9 Marietjie Venter,1,18 and Cheryl Cohen6,7; for the South African Severe Acute Respiratory Illness Surveillance Group

1Centers for Disease Control and Prevention, Pretoria, South Africa; 2Centers for Disease Control and Prevention, Atlanta, Georgia; 3US Public Health Service, Rockville, Maryland; 4South African Field Epidemiology Training Program, Johannesburg, 5School of Health Systems and Public Health, Faculty of Health Sciences, University of Pretoria, 6Center for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases, Johannesburg, 7School of Public Health, 8Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, Faculty of Health Sciences, 9Department of Science and Technology/National Research Foundation: Vaccine Preventable Diseases, 10MRC/Wits Rural Public Health and Health Transitions Research Unit (Agincourt), School of Public Health, 11Department of Internal Medicine, and 12School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; 13Centre for Global Health Research, Umeå University, Sweden; 14INDEPTH Network, Accra, Ghana; 15Pietermaritzburg Metropolitan Hospital Complex, 16University of KwaZulu-Natal, Durban, 17Department of Internal Medicine, Klerksdorp-Tshepong Hospital Complex, 18Department of Medical Virology, Zoonoses Research Unit, University of Pretoria, 19National Health Laboratory Service, Tshwane Academic Division, and 20Medical Research Council, Pretoria, South Africa

Background. Parainfluenza virus (PIV) is a common cause of acute respiratory tract infections, but little is known about PIV infection in children and adults in Africa, especially in settings where human immunodeficiency virus (HIV) prevalence is high.

Methods. We conducted active, prospective sentinel surveillance for children and adults hospitalized with severe acute respiratory illness (SARI) from 2009 to 2014 in South Africa. We enrolled controls (outpatients without febrile or respiratory illness) to calculate the attributable fraction for PIV infection. Respiratory specimens were tested by multiplex real-time reverse-transcription polymerase chain reaction assay for parainfluenza types 1, 2, and 3.

Results. Of 18 282 SARI cases enrolled, 1188 (6.5%) tested positive for any PIV type: 230 (19.4%) were type 1; 168 (14.1%) were type 2; 762 (64.1%) were type 3; and 28 (2.4%) had coinfection with 2 PIV types. After adjusting for age, HIV serostatus, and respiratory viral coinfection, the attributable fraction for PIV was 65.6% (95% CI [confidence interval], 47.1–77.7); PIV contributed to SARI among HIV-infected and -uninfected children <5 years of age and among individuals infected with PIV types 1 and 3. The observed overall incidence of PIV-associated SARI was 38 (95% CI, 36–39) cases per 100 000 population and was highest in children <1 year of age (925 [95% CI, 864–989] cases per 100 000 population). Compared with persons without HIV, persons with HIV had an increased relative risk of PIV hospitalization (9.4; 95% CI, 8.5–10.3).

Conclusions. Parainfluenza virus causes substantial severe respiratory disease in South Africa among children <5 years of age, especially those that are infected with HIV.

Keywords. HIV; parainfluenza virus; severe acute respiratory illness; South Africa.
Parainfluenza virus (PIV) is a paramyxovirus commonly detected in patients with respiratory illness, such as upper respiratory tract infections, laryngotracheobronchitis (croup), or pneumonia. There are 4 distinct types: 1, 2, 3, and 4. Parainfluenza virus infection is most common in childhood, and serologic surveys have shown that nearly all children have antibodies to PIV by 5 years of age [1, 2]. Parainfluenza virus is associated with 3%–10% of hospitalized respiratory tract infections in children and adults [3–10]. Parainfluenza virus infections occur throughout the year, but there are recognized patterns of seasonality associated with different types [11]. The clinical significance of identifying PIV infection among patients with respiratory illness does not necessarily imply causation because the virus may be found in individuals without respiratory symptoms [12].

In South Africa, human immunodeficiency virus (HIV) is prevalent, which impacts respiratory disease burden [13]. In 2009, the national HIV prevalence estimate among children <5 years was 4.1% and decreased to 3.5% by 2013; the HIV prevalence among adults ≥18 years of age was approximately 16.0% during the same time [14]. A study from Soweto prior to availability of antiretroviral therapy (ART) found that HIV-infected children with PIV-associated lower respiratory tract infection had greater morbidity and mortality than HIV-uninfected children [15]. A more recent study from Cape Town found that PIV was associated with 12% of viral-associated pediatric intensive care unit admissions [16]. Previous studies from our group have detected PIV in 2.8% of adults and 9.4% of children hospitalized with severe acute respiratory illness [17–19].

Little is known about the epidemiology of PIV infection, including its association with illness and its clinical manifestation among both HIV-infected and -uninfected children and adults in South Africa, especially in the era of ART management. In this study, we aimed to describe the epidemiological and clinical characteristics of HIV-infected and -uninfected children and adults hospitalized with PIV-associated pneumonia in South Africa. In addition, we compared the prevalence of PIV detection with controls for better interpretation of surveillance data.

METHODS

Setting and Time Period
We conducted surveillance for children and adults hospitalized with pneumonia through the Severe Acute Respiratory Illness (SARI) Program, an active, prospective, sentinel hospital-based surveillance system in 4 provinces in South Africa, as described previously [13]. In February 2009, SARI surveillance began in 3 of the 9 provinces of South Africa (Chris Hani-Baragwanath Academic Hospital [CHBAH], an urban site in Gauteng Province; Edendale Hospital, a periurban site in KwaZulu-Natal Province; and Matikwana and Mapulang Hospitals, rural sites in Mpumalanga Province). In June 2010, an additional surveillance site was introduced at the Klerksdorp-Tshepong Hospital Complex, periurban sites in North West Province. We stopped enrolling at CHBAH in December of 2013. In addition to SARI cases, controls were enrolled from May 2012 to 2 outpatient clinics serving the same population as 2 of the SARI sentinel sites: Edendale Hospital Gateway Clinic, KwaZulu-Natal Province, and Jouberton Clinic, North West Province. The case definitions used and enrollment procedures for both SARI cases and controls are described fully in the Supplementary Material.

This surveillance, including testing for influenza and HIV, received human subjects review and ethics approval by the Universities of the Witwatersrand, KwaZulu-Natal, and Pretoria, all of South Africa. The Centers for Disease Control and Prevention (Atlanta, GA) deemed this a nonresearch, surveillance activity.

Laboratory Methods
Nasopharyngeal aspirates from patients aged <5 years and nasopharyngeal and throat swabs from patients aged ≥5 years were placed in viral transport media, kept at 4–8°C, and sent to the National Institute for Communicable Diseases (NICD) in Johannesburg within 72 hours of collection. Respiratory specimens were tested by multiplex real-time, reverse-transcription polymerase chain reaction (PCR) assay for 10 respiratory viruses (PIV types 1, 2, and 3; respiratory syncytial virus [RSV]; influenza A and B viruses; enterovirus; human metapneumovirus; adenovirus, and rhinovirus) [17]. We did not test for PIV type 4 during the study period. We did not test for adenovirus from August to October 2009 because of unavailability of reagents. Streptococcus pneumoniae was identified by quantitative real-time PCR detecting the lytA gene from whole blood specimens [20]. When available, HIV-infection status data were obtained through routine standard of care testing at the treating hospital. When not available, HIV testing was implemented at NICD through anonymized, linked dried blood spot specimen testing by HIV PCR assay for children aged <18 months and by enzyme-linked immunosorbent assay for those aged ≥18 months.

Data Analysis
We conducted 3 multivariable logistic regression models. In our first analysis, we implemented univariate and multivariable logistic regression models to determine the association of PIV infection with SARI (for all types together and for each viral type separately) compared with controls enrolled from May 2012 to December 2014 at the sites in KwaZulu-Natal and North West Provinces. For the estimation of association with SARI, we conducted an overall analysis adjusting for age, HIV serostatus, respiratory viral coinfection, and underlying illness and subanalyses stratifying by age and HIV serostatus and...
adjusting for respiratory viral coinfection and underlying illness. Then, we estimated the attributable fraction (AF) from the odds ratio (OR) obtained from the multivariable model using the following formula: AF = (OR-1)/OR × 100. In our second analysis, univariate and multivariable logistic regression was used to determine factors associated with HIV infection among patients with PIV-associated SARI from January 2009 to December 2014 at all SARI sites. In our third analysis, we used multinomial regression to compare and contrast demographic and clinical characteristics and severity among patients infected with the 3 PIV types. For the multinomial analysis, we used PIV type 3 as the baseline category because type 3 is most common.

The second and third analyses models were built using manual backward elimination in which nonsignificant variables were removed from the model one at a time starting with the variables with smallest magnitude of effect until all remaining variables had a P value of <.05. Covariates with a P value of <.2 at univariate analysis were assessed for significance with multivariable analysis; statistical significance was assessed at P < .05 for all multivariable models. Two-way interactions were assessed by inclusion of product terms for all variables remaining in the final additive models. For each univariate analysis, we used all available case information. For important variables in the HIV association and AF analyses that had substantial missing data, namely HIV infection status, we multiply imputed that variable as well as any variables that were incomplete and associated with HIV using chained equation multiple imputation over 10 iterations. When adjusting for respiratory viral coinfection in our models, we evaluated coinfection with each virus separately and also as a combined variable of coinfection with any of the tested viruses.

Calculation of observed incidence and incidence adjusted for AF of PIV-associated SARI hospitalizations was done for 1 study site (CHBAH) where population denominators were available, as described previously [13]. A complete description of the incidence calculation methods can be found in the Supplementary Material.

RESULTS

Demographic and Clinical Characteristics of Parainfluenza Virus-Associated Severe Acute Respiratory Illness

Of 22 351 SARI cases screened in surveillance from 2009 to 2014, 18 715 (83.7%) SARI cases were enrolled. Of these, 18 282 (97.7%) were tested for PIV. The majority of SARI patients was of black race (98.1%, 18 165 of 18 519) and enrolled at CHBAH (66.1%, 12 372 of 18 715). Of the SARI cases tested for PIV, 1188 (6.5%) tested positive for any PIV type: 230 (19.4%) were solely type 1, 168 (14.1%) were solely type 2, and 762 (64.1%) were solely type 3. Coinfection with 2 types of PIV occurred in 28 (2.4%) patients: 3 (0.3%) tested positive for both types 1 and 2, 13 (1.1%) for types 1 and 3, and 12 (1.0%) for both 2 and 3. Children <5 years of age were more likely to test positive for PIV (9.2%, 963 of 10 448) than individuals aged ≥5 years (2.8%, 214 of 7737, P < .001). Males were slightly more likely to test positive for PIV (7.1%, 637 of 9018) than females (5.9%, 540 of 9168, P = .001). The SARI patients who died in hospital were less likely to test positive for PIV (4.0%, 29 of 717) than those who did not (6.6%, 1142 of 17316, P = .007). There were no differences in percentage testing positive by race or surveillance site (data not shown).

Human immunodeficiency virus status was determined for 14 287 (76.3%) of SARI cases, of which 5829 (40.8%) were infected with HIV. Most of the patients with missing HIV status were children <5 years of age (30.6% [3290 of 10 754], compared with 13.3% [1038 of 7830] for individuals ≥5 years of age). On univariate analysis, SARI patients that were HIV-infected were less likely to test positive for PIV (4.0%, 230 of 5794) than those that were HIV-uninfected (7.6%, 635 of 8365, P < .001).

Attributable Fraction

During the time period when controls were enrolled (May 2012–December 2014), 1472 SARI cases were enrolled. For controls, 19 929 were screened and 1538 (7.7%) were enrolled. Overall, 97 (6.6%) of the cases and 28 (1.8%) of the controls tested positive for PIV (Table 1). The overall PIV AF was 65.6% (95% confidence interval [CI], 47.1–77.7), after adjusting for age, HIV serostatus, respiratory viral coinfection, and underlying illness, suggesting that more than two-thirds of PIV-associated SARI cases could be attributed to PIV infection. A statistically significant AF was seen among both HIV-infected (57.1%; 95% CI, 9.9–76.1) and HIV-uninfected individuals of any age (76.1%; 95% CI, 60.9–98.7); although the point estimates are different, the CIs overlap. The AF was highest among young children and older adults, although it was only statistically significant among children <5 years of age (for <1 year, 64.9%, 95% CI, 25.4–85.3; for 1–4 years, 77.3%, 95% CI, 46.2–90.3); this same association among children <5 years of age was seen among both HIV-infected and -uninfected individuals.

We then calculated the AF for PIV types 1, 2, and 3 separately. The AF was 73.1% (95% CI, 41.2–87.8) for PIV type 1, 61.1% (95% CI, 0–92.9) for PIV type 2, and 60.3% (95% CI, 33.3–76.5) for PIV type 3. The age and HIV-status subgroup analysis results for PIV types 1 and 3 separately were similar to those found for parainfluenza overall, except that some subgroup analyses involved smaller numbers of subjects and were not statistically significant (data not shown). We did not conduct the subgroup analysis for PIV type 2 because it was not found to be statistically associated with disease.
Table 1. Association of Parainfluenza Virus Infection With Severe Disease Comparing SARI Cases to Controls, by Age and HIV Serostatus—South Africa, 2012–2014

| Age Groups (in Years) | SARI Cases n/N (%) | Controls n/N (%) | Adjusted Odds Ratio (95% CI) | Attributable Fraction (95% CI) |
|-----------------------|--------------------|-----------------|----------------------------|-------------------------------|
| HIV-Infected and -Uninfected Individuals |                     |                 |                            |                               |
| <1                   | 59/699 (8.4)       | 9/213 (4.2)     | 2.85 (1.34–6.80)           | 64.9 (25.4–85.3)              |
| 1–4                  | 30/377 (8.0)       | 10/357 (2.8)    | 4.40 (1.86–10.30)          | 77.3 (46.2–90.3)              |
| 5–24                 | 3/98 (3.1)         | 6/395 (1.5)     | 2.14 (.33–10.49)           | 53.3 (0–90.5)                 |
| 25–54                | 3/230 (1.3)        | 3/322 (0.9)     | 1.30 (.16–10.65)           | 23.1 (0–90.6)                 |
| ≥55                  | 2/68 (2.9)         | 0/251 (0)       | 7.59 (.56–∞)b              | 86.8 (0–∞)                    |
| All agesc            | 97/1472 (6.6)      | 28/1538 (1.8)   | 2.91 (1.89–4.48)           | 65.6 (47.1–77.7)              |
| HIV-Infected Individualsd |                   |                 |                            |                               |
| <1                   | 6/71 (8.5)         | 1/24 (4.2)      | 2.11 (.24–101.72)          | 52.6 (0–99.0)                 |
| 1–4                  | 8/59 (13.6)        | 6/168 (3.6)     | 3.91 (1.10–14.84)          | 74.4 (9.1–93.3)               |
| 5–24                 | 1/42 (2.4)         | 3/188 (1.6)     | 1.22 (.02–16.12)           | 18.0 (0–93.8)                 |
| 25–54                | 2/199 (1.0)        | 3/189 (1.6)     | 0.67 (.05–6.01)            | 0 (0–83.4)                    |
| ≥55                  | 1/25 (4.0)         | 0/94 (0)        | 1.88 (.05–∞)b              | 46.8 (0–∞)                    |
| All agesc            | 18/396 (4.6)       | 13/663 (2.0)    | 2.33 (1.11–4.18)           | 57.1 (9.9–76.1)               |
| HIV-Uninfected Individualsd |                |                 |                            |                               |
| <1                   | 53/628 (8.4)       | 8/189 (4.2)     | 3.16 (1.41–8.09)           | 68.4 (29.1–87.6)              |
| 1–4                  | 22/318 (6.9)       | 4/189 (2.1)     | 4.88 (1.49–21.13)          | 79.5 (32.9–95.3)              |
| 5–24                 | 2/56 (3.6)         | 3/207 (1.5)     | 4.08 (.32–37.96)           | 75.5 (0–97.4)                 |
| 25–54                | 1/31 (3.2)         | 0/133 (0)       | 4.57 (.12–∞)b              | 78.1 (0–∞)                    |
| ≥55                  | 1/43 (2.3)         | 0/157 (0)       | 4.40 (.11–∞)b              | 77.3 (0–∞)                    |
| All agesc            | 79/1076 (7.3)      | 15/875 (1.7)    | 4.19 (2.56–7.79)           | 76.1 (60.9–98.7)              |

Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; SARI, severe acute respiratory illness.

a Odds ratio adjusted for HIV serostatus, respiratory viral coinfection, and underlying illness.

b Exact logistic regression used because of zero cells.

c Multiply imputed dataset used to address missing data; the original dataset was used for the other subanalyses in this table because the numbers in separate strata were too small for regression on a multiply imputed dataset.

d Odds ratio adjusted for respiratory viral coinfection and underlying illness.

Factors Associated With Human Immunodeficiency Virus Infection and Viral Type

Most (81.8%, 1043 of 1188) patients with PIV-associated SARI were <5 years of age, the group for which we found a statistically significant and substantial AF. Twelve percent (11.9%, 80 of 675) of children <5 years of age with PIV-associated SARI were infected with HIV (Table 2). The case-fatality rate among children <5 years of age was 1.6% (15 of 952). On multivariable analysis among children <5 years of age with PIV-associated SARI, HIV-infected children were more likely to be older (adjusted OR [aOR] 2.4, 95% CI, 1.4–4.0, for 1- to 4-year-olds compared with <1-year-olds) and have pneumococcal coinfection (aOR 4.8, 95% CI, 2.0–11.6; Table 2) than HIV-uninfected children. Among children, HIV-infection was neither more nor less likely to be associated with prolonged hospitalization ≥3 days or death; both outcomes were not statistically significantly associated with HIV-infection on multivariable analysis and were not included in the final model. Compared with children <5 years of age, individuals ≥5 years of age with PIV-associated SARI had a higher rate of HIV infection (79.0% [150 of 190] in ≥5 years and 11.9% [80 of 675] in <5 years, P < .001) and higher case/fatality ratio (6.4% [14 of 219] in ≥5 years and 1.6% [15 of 952] in <5 years, P < .001; Tables 2 and 3). On multivariable analysis among individuals ≥5 years of age with PIV-associated SARI, HIV-infected individuals were more likely to be young adults 25–44 years of age (aOR 5.2, 95% CI, 1.7–15.7), compared with children and young adults (5–24 years of age), and less likely to have an underlying illness other than HIV (aOR 0.2, 95% CI, 1.1–8; Table 3).

When we compared epidemiologic and clinical characteristics of the 3 PIV types, we found statistically significant differences in age, year of infection, and coinfection with other respiratory viruses (Supplementary Table 1). On multivariable multinomial analysis, patients with PIV type 3 infection were more likely to be <1 year of age and patients with PIV type 2 infection were more likely to be 5–44 years of age, compared with patients with other PIV types. Compared with SARI patients with PIV type 3 infection, patients with either type
### Table 2. Clinical and Epidemiologic Characteristics Associated With Being HIV-Infected Among Children <5 Years of Age Hospitalized With PIV-Associated Severe Acute Respiratory Illness at 4 Sentinel Surveillance Sites—South Africa, 2009–2014

| Characteristic | All Parainfluenza Patients n/N (%) | HIV-Infected n/N (%) | HIV-Uninfected n/N (%) | Crude Odds Ratio (95% CI)<sup>b</sup> | Adjusted Odds Ratio (95% CI)<sup>b</sup> |
|---------------|------------------------------------|----------------------|------------------------|----------------------------------------|----------------------------------------|
| **Demographic characteristics** | | | | | |
| Age group | | | | | |
| <1 year | 609/963 (63.2) | 37/80 (46.3) | 407/595 (68.4) | Reference | Reference |
| 1–4 years | 354/963 (36.8) | 43/80 (53.8) | 188/595 (31.6) | 2.3 (1.4–3.8) | 2.4 (1.4–4.0) |
| Male sex | 571/963 (59.3) | 42/80 (52.5) | 346/595 (58.2) | 1.2 (1.8–1.9) | |
| Black race | 946/963 (98.6) | 79/80 (98.8) | 586/595 (98.7) | 0.9 (1.1–6.5) | |
| Hospital site | | | | | |
| CHBAH | 622/963 (64.6) | 31/80 (38.8) | 369/595 (62.1) | Reference | Reference |
| Matikwane/Mapulaneng | 135/963 (14.0) | 20/80 (25.0) | 88/595 (14.8) | 2.5 (1.4–4.3) | 2.1 (1.2–3.8) |
| Edendale | 126/963 (13.1) | 14/80 (17.5) | 89/595 (15.0) | 1.8 (0.9–3.7) | 1.7 (0.8–3.6) |
| KTHC | 80/963 (8.3) | 15/80 (18.8) | 49/595 (8.2) | 3.4 (1.7–6.7) | 3.4 (1.7–6.8) |
| Year | | | | | |
| 2009 | 232/963 (24.1) | 15/80 (18.8) | 102/595 (17.1) | Reference | Reference |
| 2010 | 146/963 (15.2) | 16/80 (20.0) | 98/595 (16.5) | 1.2 (0.6–2.7) | |
| 2011 | 273/963 (28.4) | 22/80 (27.5) | 197/595 (33.1) | 0.9 (0.4–1.8) | |
| 2012 | 146/963 (15.2) | 9/80 (11.3) | 93/595 (15.6) | 0.9 (0.4–2.0) | |
| 2013 | 122/963 (12.7) | 11/80 (13.8) | 80/595 (13.5) | 1.1 (0.5–2.6) | |
| 2014 | 44/963 (4.6) | 7/80 (8.8) | 25/595 (4.2) | 2.1 (0.8–5.6) | |
| **Coinfections and underlying medical conditions** | | | | | |
| HIV infection | 80/675 (11.9) | Not applicable | Not applicable | Not applicable | |
| Underlying illness (excluding HIV and tuberculosis infection)<sup>c</sup> | 49/962 (5.1) | 4/80 (5.0) | 30/595 (5.0) | 1.2 (0.4–3.7) | |
| Prematurity (<37 weeks gestational age at birth) | 36/963 (3.7) | 3/80 (3.8) | 25/595 (4.2) | 0.9 (0.2–3.4) | |
| Bacterial or viral respiratory coinfection | | | | | |
| Pneumococcal coinfection on PCR | 66/734 (9.0) | 12/60 (20.0) | 23/439 (5.2) | 4.6 (2.0–10.4) | 4.8 (2.0–11.6) |
| Any viral respiratory coinfection<sup>d</sup> | 567/915 (62.0) | 45/79 (57.0) | 333/563 (59.2) | 0.9 (0.6–1.4) | |
| Respiratory syncytial virus | 88/963 (9.1) | 6/80 (7.5) | 50/595 (8.4) | 0.8 (0.4–1.8) | |
| Influenza | 35/963 (3.6) | 2/80 (2.5) | 21/595 (3.5) | 0.9 (0.2–3.0) | |
| Adenovirus | 211/859 (24.6) | 19/75 (25.3) | 121/538 (22.5) | 1.1 (0.6–1.9) | |
| Rhinovirus | 313/963 (32.5) | 29/80 (36.3) | 179/595 (30.1) | 1.2 (0.8–1.9) | |
| Enterovirus | 104/963 (10.8) | 7/80 (8.8) | 57/595 (9.6) | 0.9 (0.4–1.9) | |
| Human metapneumovirus | 27/963 (2.8) | 2/80 (2.5) | 17/595 (2.9) | 0.7 (0.2–3.0) | |
| **Clinical presentation and course** | | | | | |
| Symptoms ≥3 days before admission | 271/952 (28.5) | 26/80 (73.3) | 186/589 (31.8) | 1.2 (0.7–1.8) | |
| Fever (temperature ≥38°C) | 697/958 (72.8) | 59/80 (73.8) | 423/591 (71.6) | 1.1 (0.6–1.8) | |
| Admission to intensive care | 11/947 (1.2) | 0/77 (0) | 10/589 (1.7) | 0.5 (0.3–4)<sup>e</sup> | |
| Oxygen therapy | 33/947 (35.1) | 33/77 (42.9) | 200/589 (34.5) | 1.4 (0.8–2.2) | |
| Antibiotics prescribed on admission | 859/941 (91.3) | 76/78 (98.7) | 533/581 (91.7) | 2.8 (0.6–13.3) | |
| **Outcome** | | | | | |
| Prolonged hospitalization (≥3 days) | 464/945 (49.1) | 51/77 (66.2) | 295/586 (50.3) | 1.8 (1.1–2.9) | |
| In-hospital death (case/fatality ratio) | 15/952 (1.6%) | 3/78 (3.9) | 7/591 (1.2) | 2.5 (1.7–9.3) | |

Abbreviations: CHBAH, Chris Hani-Baragwanath Academic Hospital; CI, confidence interval; HIV, human immunodeficiency virus; KTHC, Klerksdorp-Tshepong Hospital Complex; PCR, polymerase chain reaction; PIV, parainfluenza virus.

<sup>a</sup> Adjusted odds ratios are only shown if those variables were included in the final multivariable model.

<sup>b</sup> Crude and adjusted odds ratios used a dataset where multiple imputation was used to complete variables that were statistically significantly associated with HIV status or had high rates of missingness: age group, hospital site, and pneumococcal coinfection.

<sup>c</sup> Asthma, other chronic lung disease, chronic heart disease, liver disease, renal disease, diabetes mellitus, obesity, immunocompromising conditions (excluding HIV infection), neurologic disease, prematurity, kwashiorkor. These conditions were considered absent if recorded as such or if there was no direct mention of the condition in the medical records.

<sup>d</sup> Coinfection with PIV and ≥1 of the following: adenovirus, enterovirus, influenza A and B viruses, respiratory syncytial virus, human metapneumovirus, and rhinovirus. Adenovirus testing was not done August–October 2009.

<sup>e</sup> Nonmultiply imputed dataset used; exact logistic regression for zero cells unable to be used with multiple imputation.
Table 3. Clinical and Epidemiologic Characteristics Associated With Being HIV-Infected Among Children ≥5 Years of Age and Adults Hospitalized With PIV-Associated Severe Acute Respiratory Illness at 4 Sentinel Surveillance Sites—South Africa, 2009–2014a

| Characteristic                              | All Parainfluenza Patients, n/N (%) | HIV-Infected, n/N (%) | HIV-Uninfected, n/N (%) | Crude Odds Ratiob (95% CI) | Adjusted Odds Ratio (95% CI) |
|---------------------------------------------|-------------------------------------|-----------------------|-------------------------|---------------------------|-----------------------------|
| **Demographic characteristics**             |                                     |                       |                         |                           |                             |
| **Age group**                               |                                     |                       |                         |                           |                             |
| 5–24 years                                  | 46/214 (21.5)                       | 24/150 (16.0)         | 11/38 (29.0)            | Reference                 | Reference                   |
| 25–44 years                                 | 109/214 (50.9)                      | 89/150 (57.3)         | 7/38 (18.4)            | 5.6 (1.9–16.3)            | 5.2 (1.7–15.7)              |
| 45–64 years                                 | 45/214 (21.0)                       | 34/150 (22.7)         | 10/38 (26.3)            | 1.5 (1.5–4.0)            | 1.9 (0.6–5.9)              |
| ≥65 years                                   | 14/214 (6.5)                        | 3/150 (2.0)           | 10/38 (26.3)            | 0.1 (0–6)                | 0.2 (0–8)                 |
| **Male sex**                                | 66/214 (30.8)                       | 39/150 (26.0)         | 16/38 (42.1)            | 2.3 (1.0–5.0)c           | 2.9 (1.1–8.0)              |
| **Race**                                    | 208/212 (98.1)                      | 148/150 (98.7)        | 34/36 (94.4)            | 0.2 (0–1.7)              |                             |
| **Site**                                    |                                     |                       |                         |                           |                             |
| CHBAH                                       | 172/225 (76.4)                      | 117/150 (78.0)        | 28/40 (70.0)            | Reference                |                             |
| Matikwane/Mapulaneng                        | 29/225 (12.9)                       | 19/150 (12.7)         | 6/40 (15.0)             | 0.8 (.3–2.2)             |                             |
| Edendale                                    | 18/225 (8.0)                        | 12/150 (8.0)          | 2/40 (5.0)              | 1.1 (.3–4.4)             |                             |
| KTHC                                        | 6/225 (2.7)                         | 2/150 (1.3)           | 4/40 (10.0)             | 0.1 (.0–7)               |                             |
| **Year**                                    |                                     |                       |                         |                           |                             |
| 2009                                        | 66/225 (29.3)                       | 42/150 (28.0)         | 9/40 (22.5)             | Reference                |                             |
| 2010                                        | 49/225 (21.8)                       | 39/150 (26.0)         | 5/40 (12.5)             | 1.4 (.5–4.6)             |                             |
| 2011                                        | 56/225 (24.9)                       | 40/150 (26.7)         | 14/40 (35.0)            | 0.6 (.2–1.6)             |                             |
| 2012                                        | 36/225 (16.0)                       | 20/150 (13.3)         | 8/40 (20.0)             | 0.5 (0.2–1.5)            |                             |
| 2013                                        | 13/225 (5.8)                        | 8/150 (5.3)           | 2/40 (5.0)              | 0.9 (0.2–4.4)            |                             |
| 2014                                        | 5/225 (2.2)                         | 1/150 (0.7)           | 2/40 (5.0)              | 0.2 (0.0–1.7)d           |                             |
| **Coinfections and underlying medical conditions** |                                     |                       |                         |                           |                             |
| HIV infection                               | 150/190 (79.0)                      | Not applicable        | Not applicable          | Not applicable           |                             |
| Underlying illness (excluding HIV and tuberculosis infection)d | 21/214 (9.8)                      | 9/150 (6.0)           | 12/38 (31.6)            | 0.1 (.1–4)               | 0.2 (.1–8)                 |
| **Bacterial or viral respiratory coinfection** |                                     |                       |                         |                           |                             |
| Pneumococcal coinfection on PCR             | 31/199 (15.6)                       | 26/149 (17.5)         | 3/38 (7.9)              | 2.4 (1.7–8.6)            |                             |
| Any viral respiratory coinfectionb         | 68/196 (34.7)                       | 39/129 (30.2)         | 9/35 (25.7)             | 1.1 (0.6–2.4)            |                             |
| Respiratory syncytial virus                | 11/225 (4.9)                        | 6/150 (4.0)           | 1/40 (2.5)              | 1.0 (1–7.1)              |                             |
| Influenza                                   | 16/225 (7.1)                        | 13/150 (8.7)          | 2/40 (5.0)              | 1.8 (0.4–8.1)            |                             |
| Adenovirus                                  | 20/189 (10.6)                       | 9/123 (7.3)           | 4/34 (11.8)             | 0.7 (0.2–2.4)            |                             |
| Rhinovirus                                  | 39/225 (17.3)                       | 22/150 (14.7)         | 5/40 (12.5)             | 1.0 (0.4–2.7)            |                             |
| Enterovirus                                 | 2/225 (0.9)                         | 1/150 (0.7)           | 0/40 (0)                | 0.3 (0–0.1)e             |                             |
| Human metapneumovirus                      | 2/225 (0.9)                         | 1/150 (0.7)           | 0/40 (0)                | 0.3 (0–0.1)e             |                             |
| **Clinical presentation and course**        |                                     |                       |                         |                           |                             |
| Symptoms ≥3 days before admission           | 136/209 (65.1)                      | 99/146 (67.8)         | 37/63 (57.1)            | 1.4 (1.7–3.0)            |                             |
| Fever (temperature ≥38°C)                   | 191/212 (90.1)                      | 137/148 (92.6)        | 31/81 (38.3)            | 2.4 (1.9–6.5)            |                             |
| Admission to intensive care                | 0/220 (0)                           | 0/150 (0)             | 0/39 (0)                | Uncalculable             |                             |
| Oxygen therapy                             | 83/220 (37.7)                       | 58/150 (39.3)         | 13/61 (21.3)            | 1.4 (0.7–3.0)            |                             |
| Antibiotics prescribed on admission        | 203/208 (96.7)                      | 147/148 (99.3)        | 56/39 (94.6)            | 10.5 (1.1–105.1)         |                             |
| **Outcome**                                 |                                     |                       |                         |                           |                             |
| Prolonged hospitalization (≥3 days)         | 182/214 (85.1)                      | 136/150 (90.7)        | 26/38 (76.3)            | 3.3 (.4–8.0)             |                             |
| In-hospital death (case-fatality ratio)     | 14/219 (6.4)                        | 10/149 (6.7)          | 3/38 (8.3)              | 1.4 (1.3–6.3)            |                             |

Abbreviations: CHBAH, Chris Hani-Baragwanath Academic Hospital; CI, confidence interval; HIV, human immunodeficiency virus; KTHC, Klerksdorp-Tshepong Hospital Complex; PCR, polymerase chain reaction; PIV, parainfluenza virus.

a Adjusted odds ratios are only shown if those variables were included in the final multivariable model.
b Crude and adjusted odds ratios used a dataset where multiple imputation was to complete variables that were statistically significantly associated with HIV status or had high rates of missingness: age group and underlying illness.
c P > .05.
d Asthma, other chronic lung disease, chronic heart disease, liver disease, renal disease, diabetes mellitus, obesity, immunocompromising conditions (excluding HIV infection), neurologic disease, prematurity, kwashiorkor. These conditions were considered absent if recorded as such or if there was no direct mention of the condition in the medical records.
e Confinement with PIV and ≥1 of the following: adenovirus, enterovirus, influenza A and B viruses, respiratory syncytial virus, human metapneumovirus, and rhinovirus. Adenovirus testing was not done August–October 2009.
f Nonmultiply imputed dataset used; exact logistic regression for small numbers unable to be used with multiple imputation.
1 or 2 infection were more likely to be coinfected with RSV (for type 1, aOR 2.2, 95% CI, 1.3–3.7; for type 2, aOR 3.3, 95% CI, 1.9–5.7). In addition, patients with PIV type 2 infection were more likely to be coinfected with rhinovirus (aOR 2.0, 95% CI, 1.3–2.8) or enterovirus (aOR 2.6, 95% CI, 1.5–4.4) than patients with type 3 infection.

**Incidence**

The overall observed incidence of PIV-associated SARI in Soweto from 2009 to 2012 was 38 (95% CI, 36–39) cases per 100 000 population (Table 4). The observed incidence was highest in children <1 year of age (925 [95% CI, 864–989] cases per 100,000 population) and lowest in those 5–24 years of age (5 [95% CI, 4–6] cases per 100,000). In all age groups, the observed incidence was higher among HIV-infected compared with HIV-uninfected individuals. The subgroup with the highest incidence was HIV-infected infants <1 year of age (1361 [95% CI, 985–1834] cases per 100,000). The overall incidence adjusted for the AF was 25 cases per 100,000 (95% CI, 24–26); the age-specific adjusted incidences followed the same trend as the observed incidences (Table 4). The age-adjusted relative risk of PIV hospitalization by HIV status was 9.4 (95% CI, 8.5–10.3), and it was highest for children and adults ≥5 years of age, especially those 5–24 years of age (relative risk 96.9 [95% CI, 62.0–151.5]). The incidence varied year to year from a low of 22 (95% CI, 20–26) cases per 100,000 population in 2012 to a high of 65 (95% CI, 61–70) cases per 100,000 population in 2009.

**Seasonality and Annual Trends**

The 3 PIV serotypes (1, 2, and 3) were found to cocirculate throughout the year and differed from year to year; seasonal peaks were observed for PIV-3 between September and November, which is spring in South Africa (Figure 1). The percentage of specimens testing positive for any PIV type varied by year, with a higher proportion of SARI positive for PIV in 2009 (8.9%, 298 of 3347), 2011 (8.5%, 329 of 3883), and 2013 (8.1%, 135 of 1666), and lower proportion in 2010 (5.2%, 195 of 3745), 2012 (4.9%, 182 of 3701), and 2014 (6.6%, 49 of 744; P < .001).

**DISCUSSION**

Parainfluenza virus is associated with a significant amount of severe respiratory disease in South Africa among children <5 years of age, especially those that are infected with HIV. The evidence for this is based on 2 of our findings: the AF and the observed incidence. Among children <5 years of age, a substantial amount of SARI is attributable to PIV, particularly types 1 and 3. The observed incidence of PIV in Soweto, South Africa, is much higher among HIV-infected individuals and is similar to other respiratory viral pathogens such as influenza and human metapneumovirus [13, 17]. Clinicians should recognize PIV as a common cause of respiratory illness in children during the spring season, especially among children that are infected with HIV, and interventions should be developed to prevent and treat PIV disease.

As we found in South Africa, studies from across the globe have found that PIV is associated with up to 10% of inpatient respiratory illness, particularly among the very young. This has been found in Bangladesh [21], China [5, 22], Thailand [23], the United States [3, 4], and in multiple countries across the African continent. In Kenya, 5.6% of individuals ≥5 years of age hospitalized with pneumonia had PIV types 1–3 detected [6]. In Ghana, 3.1% of children hospitalized with acute lower respiratory tract infection had PIV types 1–3 detected [7]. In Mozambique, 4.8% of infants <1 year and 5.1% of children <5 years of age hospitalized with acute respiratory illness tested positive for PIV [8, 24].

It can be difficult to attribute respiratory disease to a specific pathogen. Molecular tests may identify viruses in respiratory specimens that may not be causing illness, and coinfection

---

**Table 4.** Observed Incidence per 100 000 Population and 95% CIs of Parainfluenza-Associated Severe Acute Respiratory Illness—South Africa, 2009–2012

| Age            | Overall Observed Incidence (95% CI) | Overall Adjusted Incidence (95% CI) | HIV-Infected Observed Incidence (95% CI) | HIV-Uninfected Observed Incidence (95% CI) | Relative Risk (95% CI) |
|----------------|-------------------------------------|-------------------------------------|-----------------------------------------|------------------------------------------|------------------------|
| ≤1 years       | 925 (864–989)                       | 600 (561–642)                      | 1361 (985–1834)                        | 909 (848–974)                           | 1.5 (1.1–2.0)          |
| 1–4 years      | 120 (110–132)                       | 93 (85–102)                        | 405 (317–511)                          | 107 (965–118)                          | 3.7 (2.9–4.8)          |
| 5–24 years     | 5 (4–6)                             | 3 (2–3)                            | 138 (106–174)                          | 1 (0–2)                                 | 96.9 (62.0–151.5)      |
| 25–44 years    | 21 (19–23)                          | 5 (4–5)                            | 85 (76–94)                             | 2 (1–3)                                 | 39.5 (27.0–57.7)       |
| 45–64 years    | 20 (17–23)                          | 5 (4–5)                            | 124 (104–147)                          | 5 (3–6)                                 | 26.9 (18.5–39.2)       |
| ≥65 years      | 16 (12–22)                          | 14 (10–19)                         | 0 (0–103)                              | 17 (12–22)                              | Not calculable         |
| All ages       | 38 (36–39)                          | 25 (24–26)                         | 112 (104–121)                          | 28 (27–30)                              | 9.4 (8.5–10.3)         |

Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; SARI, severe acute respiratory illness.

a Adjusted for attributable fraction.

b No HIV-infected patients ≥65 years of age with parainfluenza-associated SARI were identified during the study period.
with other potentially pathogenic respiratory viral infections was common in our population. We found that a majority of SARI was attributable to PIV types 1 and 3 in children, even when controlling for viral respiratory coinfection, but not all studies have found that PIV is pathogenic. In fact, very few studies have adequately evaluated PIV in the context of controls. Two studies from Kenya that compared patients with respiratory illness to controls did not find a statistically significant attributable risk for PIV [6, 12]. However, a study comparing children <5 years of age from Thailand hospitalized with pneumonia to controls found findings similar to ours, specifically that infection with PIV types 1 or 3 was associated with disease [25].

The lower incidence and nonsignificant AF from our data among individuals ≥5 years of age suggests that PIV infection may not be associated with respiratory disease in older children and adults. We did not find a significant AF for patients infected with PIV type 2, but we may not have been powered to detect this because type 2 was the least common type.

We found differences among patients infected with different types of PIV and between patients infected and uninfected with HIV. In children, patients with PIV-associated SARI who were HIV-infected were more likely to be older and to be coinfected with pneumococcus; however, the AF among adults was not statistically significant. The association between respiratory viral and pneumococcal infection, although not described previously for PIV infection, is well described for other pathogens such as influenza [26] and RSV [27]. Pneumococcal conjugate vaccine was introduced in the South Africa childhood immunization system in 2009, so it was available and being used during the entire time of this study.

The seasonality of PIV in South Africa is similar to that seen in other temperate countries such as the United States, where PIV circulates during the northern hemisphere spring and winter seasons [28]. In contrast, in tropical and subtropical countries in Africa, such as Cameroon, Ghana, and Kenya, PIV does not appear to have distinct seasonality [6, 7, 29].

This is one of few studies that describe the epidemiology of PIV in both children and adults over a long period and in the context of controls. However, there were some limitations to our study. Not all children were tested for HIV, and we did not analyze PIV in cases of milder outpatient influenza-like illness, which includes common presentations of PIV illness such as croup. Although it is uncommon and uncommonly tested for, we did not test for PIV type 4, so our incidence estimates would be a minimum estimate. We also did not test for all viral respiratory pathogens, such as coronavirus and bocavirus. The large number of patients from CHBAH (70%) may bias results toward the epidemiology at that one site. Our calculation of incidence was for only 1 site and the calculation of AF was conducted at 2, so these analyses may not be representative of all regions in South Africa. The incidence may be an underestimate if patients did not seek medical care for their illness or sought care at a hospital other than CHBAH or died before reaching the hospital. The increased incidence of hospitalization among individuals infected with HIV may be due to a lower threshold for hospitalization compared with HIV-uninfected individuals. Lastly, we did not have data on steroid use, which is a common treatment for croup in children, and for patients with HIV infection, we did not have information on ART nor CD4 cell count.

CONCLUSIONS

In conclusion, based on 6 years of respiratory disease surveillance, PIV is a common cause of SARI among children <5 years in South Africa. Among children, the observed incidence of PIV is higher in the HIV-infected population than the HIV-uninfected population. A vaccine to protect against PIV is not currently available, but vaccine candidates are in the clinical testing phase [30]. The findings of our study accentuate the need to target children for PIV prevention strategies including vaccination, should a vaccine against PIV become available.

Acknowledgments

We thank the surveillance officers, Severe Acute Respiratory Illness Programme team, and especially the patients. We also acknowledge Dorothy Cohen et al.
Southern of the Centers for Disease Control-South Africa for help in editing an earlier version of the manuscript; Dr. Patience Kweza of the South African Field Epidemiology and Laboratory Training Program for providing supervision and guidance during the study; and Makatsiane Pape of the Center for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases, for help with data cleaning.

Disclaimers. The contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention.

Financial support. This work was supported by the Centers for Disease Control and Prevention (Atlanta, GA), Preparedness and Response to Avian and Pandemic Influenza in South Africa (Cooperative Agreement Number: U51/IP000155-04), and the National Institute for Communicable Diseases, South Africa.

Potential conflict of interest. H. D. has received honoraria from MSD-South Africa and Novartis-South Africa, honoraria from Pfizer-South Africa for speaking engagements, and a travel grant from Novartis-South Africa.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Supplementary Material

Supplementary material is available online at Open Forum Infectious Diseases (http://OpenForumInfectiousDiseases.oxfordjournals.org/).

References

1. Stark JE, Heath RB, Peto S. A study of the antibodies against parainfluenza viruses in children’s sera. Arch Gesamte Virusforsch 1964; 14:160–8.
2. Lee MS, Mendelman PM, Sangli C, et al. Half-life of human parainfluenza virus type 3 (hPIV3) maternal antibody and cumulative proportion of hPIV3 infection in young infants. J Infect Dis 2001; 183:1281–4.
3. Weinberg GA, Hall CB, Iwane MK, et al. Parainfluenza virus infection of young children: estimates of the population-based burden of hospitalization. J Pediatr 2009; 154:694–9.
4. Counihan ME, Shay DK, Holman RC, et al. Human parainfluenza virus-associated hospitalizations among children less than 6 years of age in the United States. Pediatr Infect Dis J 2001; 20:646–53.
5. Liu WK, Liu Q, Chen DH, et al. Epidemiology and clinical presentation of the four human parainfluenza virus types. BMC Infect Dis 2013; 13:28.
6. Feikin DR, Njenga MK, Bigogo G, et al. Etiology and incidence of viral and bacterial acute respiratory illness among older children and adults in rural western Kenya, 2007–2010. PLoS One 2012; 7:e43656.
7. Kwofe TB, Anane YA, Nkrumah B, et al. Respiratory viruses in children hospitalized for acute lower respiratory tract infection in Ghana. Virol J 2012; 9:78.
8. O’Callaghan-Gordo C, Diez-Padrina N, Abacassamo F, et al. Viral acute respiratory infections among infants visited in a rural hospital of southern Mozambique. Trop Med Int Health 2011; 16:1054–60.
9. Jain S, Finelli L; CDC EIPC Study Team. Community-acquired pneumonia among U.S. children. N Engl J Med 2015; 372:615–8.
10. Jain S, Self WH, Wunderink RG, et al. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med 2015; 372:415–27.
11. Fox TG, Christenson JC. Influenza and parainfluenza viral infections in children. Pediatr Rev 2014; 35:217–27.
12. Hammit LL, Kazungu S, Morpeth SC, et al. A preliminary study of pneumonia etiology among hospitalized children in Kenya. Clin Infect Dis 2012; 54:S190–9.
13. Cohen C, Moyes J, Tempia S, et al. Severe influenza-associated lower respiratory tract infection in a high-HIV-prevalence setting-South Africa, 2009–2011. Emerg Infect Dis 2013; 19:1766–74.
14. Actuarial Society of South Africa. ASSA2008 Model, 2011. Available at: http://www.actuarialsocty.org.za/Societyactivities/CommitteeActivities/AidsCommittee/Models.aspx.
15. Madhi SA, Ramasamy N, Petersen K, et al. Severe lower respiratory tract infections associated with human parainfluenza viruses 1–3 in children infected and non-infected with HIV type 1. Eur J Clin Microbiol Infect Dis 2002; 21:499–505.
16. Ghani AS, Morrow BM, Hardie DR, et al. An investigation into the prevalence and outcome of patients admitted to a pediatric intensive care unit with viral respiratory tract infections in Cape Town, South Africa. Pediatr Crit Care Med 2012; 13:e275–81.
17. Pretorius MA, Madhi SA, Cohen C, et al. Respiratory viral coinfections identified by a 10-plex real-time reverse transcription polymerase chain reaction assay in patients hospitalized with severe acute respiratory illness-South Africa, 2009–2010. J Infect Dis 2012; 206:S159–65.
18. Cohen C, Walaza S, Moyes J, et al. Epidemiology of severe acute respiratory illness among adults and children aged ≥2 years in a high HIV-prevalence setting, 2009–2012. PLoS One 2015; 10:e0117716.
19. Cohen C, Walaza S, Moyes J, et al. Epidemiology of viral-associated acute lower respiratory tract infection among children <5 years of age in a high HIV prevalence setting, South Africa, 2009–2012. Pediatr Infect Dis J 2015; 34:66–72.
20. Carvalho Mda G, Tondella ML, McCaustland K, et al. Evaluation and improvement of real-time PCR assays targeting lytA, ply, and psaA genes for detection of pneumococcal DNA. J Clin Microbiol 2007; 45:2460–6.
21. Nasreen S, Luby SP, Brooks WA, et al. Population-based incidence of severe acute respiratory virus infections among children aged <5 years in rural Bangladesh, June-October 2010. PLoS One 2014; 9:e89978.
22. Feng L, Li Z, Zhao S, et al. Viral etiologies of hospitalized acute lower respiratory infection patients in China, 2009–2013. PLoS One 2014; 9: e99419.
23. Morgan OW, Chittaganpitch M, Cagle B, et al. Hospitalization due to human parainfluenza virus-associated lower respiratory tract illness in rural Thailand. Influenza Other Respir Viruses 2013; 7:280–5.
24. O’Callaghan-Gordo C, Bassat Q, Morais L, et al. Etiology and epidemiology of viral pneumonia among hospitalized children in rural Mozambique: a malaria endemic area with high prevalence of human immunodeficiency virus. Pediatr Infect Dis J 2011; 30:39–44.
25. Hasan R, Rhodes J, Thamthitwiwat S, et al. Incidence and etiology of acute lower respiratory tract infections in hospitalized children younger than 5 years in rural Thailand. Pediatr Infect Dis J 2014; 33:e45–52.
26. Madhi SA, Schoub B, Klugman KP. Interaction between influenza virus and Streptococcus pneumoniae in severe pneumonia. Expert Rev Resp Med 2008; 2:663–72.
27. Weinberger DM, Klugman KP, Steiner CA, et al. Association between respiratory syncytial virus activity and pneumococcal disease in infants: a time series analysis of US hospitalization data. PLoS Med 2015; 12:e1001776.
28. Fry AM, Curns AT, Harbour K, et al. Seasonal trends of human parainfluenza viral infections: United States, 1990–2004. Clin Infect Dis 2006; 43:1016–22.
29. Njouom R, Yekwa EL, Cappy P, et al. Viral etiology of influenza-like illnesses in Cameroon, January–December 2009. J Infect Dis 2012; 206: S29–35.
30. Schmidt AC, Schaap-Nutt A, Bartlett EJ, et al. Progress in the development of human parainfluenza virus vaccines. Expert Rev Resp Med 2011; 5:515–26.

Parainfluenza Illness in South Africa • OFID • 9